Interv Akut Kardiol. 2023;22(1):49-51 | DOI: 10.36290/kar.2023.008
Cangrelor and its use in a patient with acute coronary syndrome
- 1 Interní kardiologická klinika Fakultní nemocnice Brno
- 2 Lékařská fakulta Masarykovy univerzity Brno
Nowadays, cangrelor is still the only intravenous antiplatelet drug that belongs to the P2Y12 inhibitors family. Its unique characteristics are possibilities of intravenous application and rapid onset and offset of action. In this case, we would like to present a patient with acute myocardial infarction in whom percutaneous coronary intervention could be very dangerous without the use of cangrelor. The reason was very high ischemic risk during complex coronary intervention. In addition to this indication, cangrelor could be very useful in other situations, when intravenous administration is the only way to inhibit platelets.
Keywords: cangrelor, Kengrexal®, intravenous antiplatelet agens, intravenous P2Y12 inhibitors.
Accepted: March 27, 2023; Published: April 12, 2023 Show citation
References
- Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient‑level data. The Lancet. 2013 Dec 14;382(9909):1981-92.
Go to original source... 
Go to PubMed... - Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. J Clin Pharmacol. 2010 Jan;50(1):27-35. Go to original source... Go to PubMed...
- Varvařovský I. Cangrelor (KENGREXAL®) - nový starý známý. Interv Akutní Kardiologie. 2020 Jun 1;19(1):63-6. Go to original source...
- Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N Engl J Med. 2009 Dec 10;361(24):2318-29. Go to original source... Go to PubMed...
- Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST‑Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study. Circulation. 2019 Apr 2;139(14):1661-70. Go to original source... Go to PubMed...
- Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, et al. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST‑Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS‑FASTER Trial. Circulation. 2020 Aug 4;142(5):441-54. Go to original source... Go to PubMed...
- Rossini R, Masiero G, Fruttero C, Passamonti E, Calvaruso E, Cecconi M, et al. Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real‑World Bridging Protocol Experience. TH Open. 2020 Oct;04(04):e437-45. Go to original source... Go to PubMed...
- Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial. JAMA [Internet]. 2012 Jan 18 [cited 2023 Mar 28];307(3). Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2011.2002. Go to original source... Go to PubMed...
- European medicines Agency [Internet]. Kengrexal: European public assessment report - Product information. [cited 2023 Apr 03] Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal#product‑information‑section.
- Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017 Nov 14;136(20):1955-75. Go to original source... Go to PubMed...